Total Raised

$13.5M

Investors Count

8

Deal Terms

1

Funding, Valuation & Revenue

6 Fundings

Par8o has raised $13.5M over 6 rounds.

Par8o's latest funding round was a Acquired - III for on February 2, 2026.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

2/2/2026

Acquired - III

$XXM

0

FY undefined

3

1/1/2022

Acquired - II

$XXM

0

FY undefined

10

12/15/2021

Acquired

$XXM

0

FY undefined

10

10/8/2015

Convertible Note

$XXM

$XXM

0

FY undefined

10

1/8/2015

Series A

$XXM

$XXM

0

FY undefined

10

Date

2/2/2026

1/1/2022

12/15/2021

10/8/2015

1/8/2015

Round

Acquired - III

Acquired - II

Acquired

Convertible Note

Series A

Amount

$XXM

$XXM

Investors

Valuation

$XXM

$XXM

$XXM

$XXM

$XXM

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

3

10

10

10

10

Start free trial
New call-to-action

Par8o Deal Terms

1 Deal Term

Par8o's deal structure is available for 1 funding round, including their Series A from January 08, 2015.

Round

Series A

Funding Date

$XXM

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$XXM

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$XXM

Board Voting

$XXM

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series A

$XXM

$XXM

$XXM

$XXM

Par8o Investors

8 Investors

Par8o has 8 investors. NuvemRx invested in Par8o's Acquired - III funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

2/2/2026

2/2/2026

1
Acquired - III

Corporation

Pennsylvania

00/00/0000

00/00/0000

R1

Subscribe to see more

Corporation

Utah

00/00/0000

00/00/0000

Cloudmed

Subscribe to see more

Corporation

Georgia

00/00/0000

00/00/0000

UnitedHealth Group

Subscribe to see more

Corporation

Minnesota

00/00/0000

00/00/0000

Founder Collective

Subscribe to see more

Venture Capital

Massachusetts

First funding

2/2/2026

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Last Funding

2/2/2026

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Investor

R1

Cloudmed

UnitedHealth Group

Founder Collective

Rounds

1
Acquired - III

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Type

Corporation

Corporation

Corporation

Corporation

Venture Capital

Location

Pennsylvania

Utah

Georgia

Minnesota

Massachusetts

New call-to-action

Compare Par8o to Competitors

Massive Bio Logo
Massive Bio

Massive Bio operates as an artificial intelligence (AI) driven platform specializing in personalized oncology solutions within the healthcare sector. The company offers services connecting cancer patients and oncologists to clinical trials for new, alternative, and targeted treatments, as well as providing personalized treatment recommendations through a virtual tumor board. It primarily serves the healthcare industry, particularly oncology care providers and cancer patients seeking treatment options. It was founded in 2014 and is based in Istanbul, Turkey.

Judi Logo
Judi

Judi specializes in clinical trial workflow software within the life sciences sector. The company provides a platform that supports the clinical trials process, allowing for research that meets regulatory standards. Judi's services include support for trial sites, sponsors, CROs, and other partners in the clinical trial ecosystem. It was founded in 2005 and is based in Boston, Massachusetts.

ePHealth Logo
ePHealth

ePHealth specializes in decentralized clinical trials and operates within the healthcare industry. The company offers a clinical trial platform that integrates patient participation, recruiting sites, and coordinating centers, with a focus on trial management and patient enrollment. ePHealth primarily serves the clinical research sector, providing solutions for patients and investigators. It was founded in 2015 and is based in London, United Kingdom.

ObvioHealth Logo
ObvioHealth

ObvioHealth is a digital health organization focused on improving clinical trials through technology. The company offers a platform for conducting decentralized and hybrid clinical trials, providing services such as study design, participant recruitment, electronic consent and enrollment, data capture and monitoring, and analytics and reporting. ObvioHealth serves the healthcare sectors, including CROs, medical devices, pharmaceuticals, biotechnology, and consumer health industries. It was founded in 2017 and is based in New York, New York.

Castor Logo
Castor

Castor operates within the healthcare sector and provides a clinical trial platform designed for the design, deployment, patient engagement, data collection, and analysis of clinical trials. The platform is adaptable and can meet the requirements of different stakeholders in the clinical research process. It primarily serves the healthcare sector. The company was founded in 2012 and is based in Amsterdam, Netherlands.

Hawthorne Effect Logo
Hawthorne Effect

Hawthorne Effect offers mobile clinical research in the healthcare industry. It provides a technology-driven solution for conducting clinical trials at patients' locations, utilizing a network of healthcare professionals to ensure data quality and compliance. It serves the biopharma sectors by facilitating access to clinical trials and improving patient engagement. It was founded in 2015 and is based in Walnut Creek, California.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.